Compare Stocks: IMA, CGEN, RNAC, and ELDN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGEN Compugen	$2.13 +0.5%	$2.45	$1.43 ▼ $3.23	$200.45M	2.78	172,882 shs	123,364 shs
ELDN Eledon Pharmaceuticals	$2.48 +2.5%	$3.03	$1.35 ▼ $4.60	$196.65M	0.84	823,924 shs	817,228 shs
IMA ImageneBio	$4.24 -0.5%	$5.13	$3.90 ▼ $9.10	$48.36M	0.74	15,297 shs	8,121 shs
RNAC Cartesian Therapeutics	$7.05 +3.4%	$8.47	$5.60 ▼ $11.00	$206.34M	0.65	152,696 shs	114,546 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGEN Compugen	+0.47%	-7.79%	-14.11%	-10.88%	+17.68%
ELDN Eledon Pharmaceuticals	+2.48%	-0.40%	-12.06%	-35.58%	-13.59%
IMA ImageneBio	-0.47%	-7.83%	-15.37%	-28.26%	-48.73%
RNAC Cartesian Therapeutics	+3.37%	-4.21%	-18.87%	-25.48%	-31.09%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGEN Compugen	$2.13 +0.5%	$2.45	$1.43 ▼ $3.23	$200.45M	2.78	172,882 shs	123,364 shs
ELDN Eledon Pharmaceuticals	$2.48 +2.5%	$3.03	$1.35 ▼ $4.60	$196.65M	0.84	823,924 shs	817,228 shs
IMA ImageneBio	$4.24 -0.5%	$5.13	$3.90 ▼ $9.10	$48.36M	0.74	15,297 shs	8,121 shs
RNAC Cartesian Therapeutics	$7.05 +3.4%	$8.47	$5.60 ▼ $11.00	$206.34M	0.65	152,696 shs	114,546 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGEN Compugen	+0.47%	-7.79%	-14.11%	-10.88%	+17.68%
ELDN Eledon Pharmaceuticals	+2.48%	-0.40%	-12.06%	-35.58%	-13.59%
IMA ImageneBio	-0.47%	-7.83%	-15.37%	-28.26%	-48.73%
RNAC Cartesian Therapeutics	+3.37%	-4.21%	-18.87%	-25.48%	-31.09%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGEN Compugen	3.00	Buy	$5.00	134.74% Upside
ELDN Eledon Pharmaceuticals	2.33	Hold	$10.00	303.23% Upside
IMA ImageneBio	2.25	Hold	$29.00	583.96% Upside
RNAC Cartesian Therapeutics	2.57	Moderate Buy	$32.60	362.41% Upside

Current Analyst Ratings Breakdown

Latest IMA, CGEN, RNAC, and ELDN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/30/2026	RNAC Cartesian Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$25.00
9/29/2026	RNAC Cartesian Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00
9/25/2026	IMA ImageneBio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/21/2026	ELDN Eledon Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/9/2026	RNAC Cartesian Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/21/2026	IMA ImageneBio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$28.00
8/21/2026	IMA ImageneBio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$28.00
8/18/2026	RNAC Cartesian Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$38.00
8/5/2026	CGEN Compugen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Hold (C-)
8/4/2026	CGEN Compugen	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/29/2026	RNAC Cartesian Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold

(Data available from 10/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGEN Compugen	$72.76M	2.77	$0.38 per share	5.67	$1.09 per share	1.95
ELDN Eledon Pharmaceuticals	N/A	N/A	N/A	N/A	$1.35 per share	N/A
IMA ImageneBio	$800K	60.16	N/A	N/A	$11.91 per share	0.36
RNAC Cartesian Therapeutics	$2.80M	76.17	N/A	N/A	($4.85) per share	-1.45

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGEN Compugen	$35.34M	$0.38	5.61	N/A	N/A	47.56%	42.57%	26.13%	11/9/2026 (Estimated)
ELDN Eledon Pharmaceuticals	-$45.62M	-$0.91	N/A	N/A	N/A	N/A	-149.63%	-50.84%	11/13/2026 (Estimated)
IMA ImageneBio	-$45.35M	-$4.58	N/A	N/A	N/A	N/A	-38.99%	-34.84%	N/A
RNAC Cartesian Therapeutics	-$130.30M	-$5.94	N/A	N/A	N/A	-8,550.65%	N/A	-29.84%	11/5/2026 (Estimated)

Latest IMA, CGEN, RNAC, and ELDN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	N/A	RNAC Cartesian Therapeutics	-$1.02	N/A	N/A	N/A	$0.16 million	N/A
8/13/2026	Q2 2026	ELDN Eledon Pharmaceuticals	-$0.1580	-$0.27	-$0.1120	-$0.27	N/A	N/A
8/6/2026	Q2 2026	RNAC Cartesian Therapeutics	-$0.8779	$0.46	+$1.3379	$0.46	$0.18 million	N/A
8/5/2026	Q2 2026	IMA ImageneBio	-$0.90	-$0.63	+$0.27	-$0.63	N/A	N/A
8/3/2026	Q2 2026	CGEN Compugen	-$0.08	-$0.07	+$0.01	-$0.07	$1.29 million	$2.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGEN Compugen	N/A	N/A	N/A	N/A	N/A
ELDN Eledon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IMA ImageneBio	N/A	N/A	N/A	N/A	N/A
RNAC Cartesian Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGEN Compugen	N/A	5.72	5.72
ELDN Eledon Pharmaceuticals	N/A	7.90	7.90
IMA ImageneBio	N/A	21.47	21.47
RNAC Cartesian Therapeutics	N/A	7.48	7.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGEN Compugen	12.22%
ELDN Eledon Pharmaceuticals	56.77%
IMA ImageneBio	75.00%
RNAC Cartesian Therapeutics	86.95%

Insider Ownership

Company	Insider Ownership
CGEN Compugen	9.50%
ELDN Eledon Pharmaceuticals	9.60%
IMA ImageneBio	2.22%
RNAC Cartesian Therapeutics	37.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGEN Compugen	75	94.55 million	85.57 million	Optionable
ELDN Eledon Pharmaceuticals	33	81.26 million	73.46 million	Optionable
IMA ImageneBio	18	11.35 million	11.10 million	Not Optionable
RNAC Cartesian Therapeutics	75	30.25 million	19.00 million	Optionable

IMA, CGEN, RNAC, and ELDN Headlines

Recent News About These Companies

Cartesian Therapeutics Announces New Employment Inducement Grants - October 2, 2026

October 4, 2026 | biospace.comB

Cartesian Therapeutics Announces New Employment Inducement Grants

October 2, 2026 | globenewswire.com

Cartesian Therapeutics (NASDAQ:RNAC) Stock Rating Reaffirmed as "Buy" by HC Wainwright

October 2, 2026 | americanbankingnews.com

Needham & Company LLC Reaffirms "Buy" Rating for Cartesian Therapeutics (NASDAQ:RNAC)

October 1, 2026 | americanbankingnews.com

Cartesian Therapeutics (NASDAQ:RNAC) Earns Buy Rating from HC Wainwright

September 30, 2026 | marketbeat.com

Cartesian Therapeutics' (RNAC) Buy Rating Reaffirmed at Needham & Company LLC

September 29, 2026 | marketbeat.com

Cartesian Reports Positive Phase 2 Retreatment Data For Descartes-08

September 29, 2026 | rttnews.com

Cartesian's Descartes-08 Shows Durable Responses In Myasthenia Gravis

September 29, 2026 | rttnews.com

Cartesian Therapeutics Reports Positive Retreatment Data for Descartes-08 in Generalized Myasthenia Gravis

September 29, 2026 | quiverquant.comQ

Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis

September 29, 2026 | globenewswire.com

Analyzing Denali Therapeutics (NASDAQ:DNLI) and Cartesian Therapeutics (NASDAQ:RNAC)

September 29, 2026 | americanbankingnews.com

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Average Recommendation of "Moderate Buy" from Analysts

September 18, 2026 | marketbeat.com

Cartesian Therapeutics Announces New Employment Inducement Grants

September 8, 2026 | globenewswire.com

Cartesian Therapeutics to Participate in Upcoming Investor Conferences

September 3, 2026 | globenewswire.com

Cantor Fitzgerald Keeps Their Buy Rating on Cartesian Therapeutics (RNAC)

August 9, 2026 | theglobeandmail.com

Cartesian Therapeutics Announces New Employment Inducement Grants

August 7, 2026 | globenewswire.com

Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

August 6, 2026 | markets.businessinsider.com

Cartesian Therapeutics Reports Q2 2026 Results, Advances Descartes-08 Clinical Trials and WestGene In Vivo Partnership

August 6, 2026 | quiverquant.comQ

Cartesian Therapeutics Inc RNAC

July 12, 2026 | morningstar.comM

Cartesian Therapeutics (RNAC) Receives a Rating Update from a Top Analyst

July 2, 2026 | theglobeandmail.com

Cartesian Therapeutics Announces New Employment Inducement Grants

July 2, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IMA, CGEN, RNAC, and ELDN Company Descriptions

Compugen NASDAQ:CGEN

$2.13 +0.01 (+0.47%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$2.12 0.00 (-0.23%)

As of 10/9/2026 07:30 PM Eastern

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Eledon Pharmaceuticals NASDAQ:ELDN

$2.48 +0.06 (+2.48%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$2.48 0.00 (0.00%)

As of 10/9/2026 07:30 PM Eastern

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

ImageneBio NASDAQ:IMA

$4.26 +0.00 (+0.02%)

As of 10/9/2026 04:00 PM Eastern

ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

Cartesian Therapeutics NASDAQ:RNAC

$7.05 +0.23 (+3.37%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$7.08 +0.03 (+0.43%)

As of 10/9/2026 07:30 PM Eastern

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMA, CGEN, RNAC, and ELDN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMA, CGEN, RNAC, and ELDN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMA, CGEN, RNAC, and ELDN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IMA, CGEN, RNAC, and ELDN Company Descriptions

Compugen NASDAQ:CGEN

Eledon Pharmaceuticals NASDAQ:ELDN

ImageneBio NASDAQ:IMA

Cartesian Therapeutics NASDAQ:RNAC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMA, CGEN, RNAC, and ELDN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMA, CGEN, RNAC, and ELDN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMA, CGEN, RNAC, and ELDN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IMA, CGEN, RNAC, and ELDN Company Descriptions

Compugen NASDAQ:CGEN

Eledon Pharmaceuticals NASDAQ:ELDN

ImageneBio NASDAQ:IMA

Cartesian Therapeutics NASDAQ:RNAC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools